Hepatitis Monthly

Published by: Kowsar

The Role of M30 in Predicting the Severity of Liver Fibrosis and Inflammation in Chronic Hepatitis B Patients

Baris Yilmaz 1 , * , Bora Aktas 1 , Akif Altinbas 1 , Zeynep Ginis 2 , Gulfer Ozturk 2 , Fuat Ekiz 1 , Serta Kilincalp 1 , Murat Deveci 1 , Zahide Simsek 1 , Sahin Coban 1 , Omer Basar 1 and Osman Yuksel 1
Authors Information
1 Department of Gastroenterology, Diskapi Yildirim Beyazit Education and Research Hospital, Ankara, Turkey
2 Department of Biochemistry, Diskapi Yildirim Beyazit Education and Research Hospital, Ankara, Turkey
Article information
  • Hepatitis Monthly: September 01, 2016, 16 (9); e35640
  • Published Online: August 10, 2016
  • Article Type: Research Article
  • Received: December 20, 2015
  • Revised: June 12, 2016
  • Accepted: July 10, 2016
  • DOI: 10.5812/hepatmon.35640

To Cite: Yilmaz B, Aktas B, Altinbas A, Ginis Z, Ozturk G, et al. The Role of M30 in Predicting the Severity of Liver Fibrosis and Inflammation in Chronic Hepatitis B Patients, Hepat Mon. 2016 ; 16(9):e35640. doi: 10.5812/hepatmon.35640.

Abstract
Copyright © 2016, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Footnote
References
  • 1. Ergunay K, Balaban Y, Cosgun E, Alp A, Simsek H, Sener B, et al. Epidemiologic trends in HBV infections at a reference centre in Turkey: an 11-year retrospective analysis. Ann Hepatol. 2012; 11(5): 672-8[PubMed]
  • 2. Kose S, Olmezoglu A, Gozaydin A, Ece G. Seroprevalence of hepatitis B and C among oncology patients in Turkey. J Health Popul Nutr. 2011; 29(6): 652-5[PubMed]
  • 3. European Association For The Study Of The L. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012; 57(1): 167-85[DOI][PubMed]
  • 4. Cheong JY, Um SH, Seo YS, Shin SS, Park RW, Kim DJ, et al. A practical scoring system for predicting cirrhosis in patients with chronic viral hepatitis. Hepatogastroenterology. 2012; 59(120): 2592-7[DOI][PubMed]
  • 5. Ghavami S, Hashemi M, Kadkhoda K, Alavian SM, Bay GH, Los M. Apoptosis in liver diseases--detection and therapeutic applications. Med Sci Monit. 2005; 11(11)-45[PubMed]
  • 6. Guicciardi ME, Gores GJ. Apoptosis: a mechanism of acute and chronic liver injury. Gut. 2005; 54(7): 1024-33[DOI][PubMed]
  • 7. Oshima RG. Apoptosis and keratin intermediate filaments. Cell Death Differ. 2002; 9(5): 486-92[DOI][PubMed]
  • 8. Yilmaz Y, Dolar E, Ulukaya E, Akgoz S, Keskin M, Kiyici M, et al. Elevated serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) in patients with nonalcoholic steatohepatitis and chronic hepatitis C. Med Sci Monit. 2009; 15(4)-93[PubMed]
  • 9. Papatheodoridis GV, Hadziyannis E, Tsochatzis E, Chrysanthos N, Georgiou A, Kafiri G, et al. Serum apoptotic caspase activity as a marker of severity in HBeAg-negative chronic hepatitis B virus infection. Gut. 2008; 57(4): 500-6[DOI][PubMed]
  • 10. Eren F, Yilmaz Y, Kose S, Ozdemir FT, Yonal O, Kurt R, et al. Caspase-cleaved fragments of cytokeratin 18 in patients with chronic hepatitis B. Clin Chim Acta. 2010; 411(23-24): 2029-32[DOI][PubMed]
  • 11. Giannousis IP, Manolakopoulos SG, Hadziyannis E, Georgiou A, Papatheodoridis GV. Changes of serum levels of keratin-18 fragments in hepatitis B e antigen-negative chronic hepatitis B patients under oral antiviral therapy. Antivir Ther. 2011; 16(4): 505-14[DOI][PubMed]
  • 12. Ekiz F, Yuksel O, Kocak E, Yilmaz B, Altinbas A, Coban S, et al. Mean platelet volume as a fibrosis marker in patients with chronic hepatitis B. J Clin Lab Anal. 2011; 25(3): 162-5[DOI][PubMed]
  • 13. Yilmaz B, Basar O, Altinbas A, Ekiz F, Aktas B, Ozturk G, et al. The utility of thrombopoietin in predicting liver fibrosis in chronic hepatitis B. Int J Clin Exp Med. 2014; 7(5): 1430-4[PubMed]
  • 14. Basar O, Yimaz B, Ekiz F, Ginis Z, Altinbas A, Aktas B, et al. Non-invasive tests in prediction of liver fibrosis in chronic hepatitis B and comparison with post-antiviral treatment results. Clin Res Hepatol Gastroenterol. 2013; 37(2): 152-8[DOI][PubMed]
  • 15. Purnak T, Beyazit Y, Oztas E, Yesil Y, Efe C, Torun S, et al. Serum angiotensin-converting enzyme level as a marker of fibrosis in patients with chronic hepatitis B. J Renin Angiotensin Aldosterone Syst. 2012; 13(2): 244-9[DOI][PubMed]
  • 16. Kilicarslan A, Kahraman A, Akkiz H, Yildiz Menziletoglu S, Fingas CD, Gerken G, et al. Apoptosis in selected liver diseases. Turk J Gastroenterol. 2009; 20(3): 171-9[PubMed]
  • 17. Caner S, Altinbas A, Sayki M, Buyukcam F, Yilmaz B, Cakal E, et al. M30 does not predict the severity of hepatosteatosis, whereas adiponectin level declined with increase of ALT and the severity of hepatic steatosis. J Clin Lab Anal. 2014; 28(5): 381-5[DOI][PubMed]
  • 18. Joka D, Wahl K, Moeller S, Schlue J, Vaske B, Bahr MJ, et al. Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatology. 2012; 55(2): 455-64[DOI][PubMed]
  • 19. Yeganeh B, Rezaei Moghadam A, Alizadeh J, Wiechec E, Alavian SM, Hashemi M, et al. Hepatitis B and C virus-induced hepatitis: Apoptosis, autophagy, and unfolded protein response. World J Gastroenterol. 2015; 21(47): 13225-39[DOI][PubMed]
  • 20. Altinbas A, Coban S, Basar O, Yuksel O. Utility of M30, an apoptotic serum marker, in liver diseases. Turk J Med Sci. 2015; 45(1): 6-10[PubMed]
  • 21. Barczyk K, Kreuter M, Pryjma J, Booy EP, Maddika S, Ghavami S, et al. Serum cytochrome c indicates in vivo apoptosis and can serve as a prognostic marker during cancer therapy. Int J Cancer. 2005; 116(2): 167-73[DOI][PubMed]
  • 22. Zhili W, Deming T, Guozhen L, Jun C. Effects of hepatitis B surface and hepatitis B core antigens from hepatitis B virus genotypes B and C on in vitro apoptosis. Hepat Mon. 2007; 7(4): 217-21
  • 23. Sumer S, Aktug Demir N, Kolgelier S, Cagkan Inkaya A, Arpaci A, Saltuk Demir L, et al. The Clinical Significance of Serum Apoptotic Cytokeratin 18 Neoepitope M30 (CK-18 M30) and Matrix Metalloproteinase 2 (MMP-2) Levels in Chronic Hepatitis B Patients with Cirrhosis. Hepat Mon. 2013; 13(6): 10106[DOI][PubMed]
  • 24. Shokouhi S, Rakhshan M, Gachkar L, Khalaj E, Sazgar S. Accuracy of biochemical markers and platelet count for diagnosis of liver fibrosis staging in patients with liver fibrosis, loghman hakim and taleghani hospitals, Tehran, Iran (2000 - 2004). Hepat Mon. 2007; 7(4): 223-8
  • 25. Kim WR, Berg T, Asselah T, Flisiak R, Fung S, Gordon SC, et al. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. J Hepatol. 2016; 64(4): 773-80[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments